SG10202103003RA - Polymer protein microparticles - Google Patents

Polymer protein microparticles

Info

Publication number
SG10202103003RA
SG10202103003RA SG10202103003RA SG10202103003RA SG10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA
Authority
SG
Singapore
Prior art keywords
polymer protein
protein microparticles
microparticles
polymer
protein
Prior art date
Application number
SG10202103003RA
Inventor
Hunter Chen
Scott Walsh
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202103003R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10202103003RA publication Critical patent/SG10202103003RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
SG10202103003RA 2011-11-18 2012-11-18 Polymer protein microparticles SG10202103003RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161561525P 2011-11-18 2011-11-18

Publications (1)

Publication Number Publication Date
SG10202103003RA true SG10202103003RA (en) 2021-05-28

Family

ID=47295198

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202103003RA SG10202103003RA (en) 2011-11-18 2012-11-18 Polymer protein microparticles
SG11201402152YA SG11201402152YA (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201402152YA SG11201402152YA (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Country Status (20)

Country Link
US (4) US20130129830A1 (en)
EP (4) EP3384903B1 (en)
JP (5) JP6267649B2 (en)
KR (4) KR102218223B1 (en)
CN (2) CN105688188A (en)
AU (1) AU2012340107B2 (en)
BR (1) BR112014011915B1 (en)
CA (2) CA2855749C (en)
DK (3) DK2790681T4 (en)
ES (3) ES2909777T3 (en)
FI (1) FI2790681T4 (en)
HU (2) HUE051644T2 (en)
IL (4) IL277958B2 (en)
MX (2) MX362286B (en)
PL (3) PL3384903T3 (en)
PT (2) PT3384903T (en)
RU (2) RU2642664C2 (en)
SG (2) SG10202103003RA (en)
WO (1) WO2013075068A1 (en)
ZA (3) ZA201403379B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012045082A2 (en) 2010-10-01 2012-04-05 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2855749C (en) 2011-11-18 2020-05-26 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
DK2791160T3 (en) 2011-12-16 2022-05-30 Modernatx Inc MODIFIED MRNA COMPOSITIONS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016530294A (en) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chimeric polynucleotide
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2017106716A1 (en) * 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
SI3394093T1 (en) 2015-12-23 2022-05-31 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
JP7285220B2 (en) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
CN112203679A (en) 2018-03-02 2021-01-08 科达制药股份有限公司 IL-6 antibodies and fusion constructs and conjugates thereof
JP2022523063A (en) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド Aflibercept attributes and their characterization and modification methods
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
AU2020394428A1 (en) * 2019-11-25 2022-07-14 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN115887760A (en) * 2022-11-21 2023-04-04 娜罗曼苏(杭州)医疗生物科技有限公司 Preparation process of L-polylactic acid for injection

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
EP0939121B2 (en) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TNF-binding proteins
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
DK0661989T3 (en) 1992-09-21 1998-03-02 Upjohn Co Prolonged release protein compositions
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
ES2252746T3 (en) 1994-09-23 2006-05-16 Alexion Pharmaceuticals, Inc. PROCEDURES FOR THE TREATMENT OF ARTICULAR INFLAMMATORY DISEASE.
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0913177A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
IL137388A (en) * 1998-01-29 2005-05-17 Poly Med Inc Absorbable microparticles
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU1226901A (en) 1999-10-22 2001-05-08 Amgen, Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
FR2809309B1 (en) 2000-05-23 2004-06-11 Mainelab EXTENDED RELEASE MICROSPHERES FOR INJECTION DELIVERY
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
NZ530700A (en) 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
JPWO2003006052A1 (en) * 2001-07-09 2005-02-17 山之内製薬株式会社 Composition for sustained-release injection and method for producing the same
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
AU2003303646B2 (en) 2002-12-31 2010-03-04 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
ES2379466T3 (en) 2003-06-26 2012-04-26 Psivida Us, Inc. Bio-erasable sustained release drug delivery system
DE10339197A1 (en) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
JP2007507339A (en) * 2003-10-01 2007-03-29 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム Particle manufacturing apparatus and method
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
PL1778723T3 (en) 2004-08-17 2013-03-29 Regeneron Pharma Il-1 antagonist formulations
US20060110429A1 (en) 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
JP4744533B2 (en) 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド Spray-dried polymer type collectin protein and method for producing the same
EP3195874A1 (en) 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007130134A2 (en) * 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Controlled release microparticles
KR100722607B1 (en) * 2006-05-11 2007-05-28 주식회사 펩트론 A process of preparing microspheres for sustained release having improved dispersibility and syringeability
EP2364691B1 (en) 2006-06-16 2013-04-24 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
DE102006030166A1 (en) 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg temper
DE102006030164A1 (en) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative powders
EP1958622A1 (en) 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
WO2008109886A1 (en) 2007-03-08 2008-09-12 The Regents Of The University Of California Topographically engineered structures and methods for using the same in regenerative medicine applications
US9775932B2 (en) 2007-03-16 2017-10-03 The Regents Of The University Of California Nanostructure surface coated medical implants and methods of using the same
KR100805208B1 (en) * 2007-03-27 2008-02-21 주식회사 펩트론 Composition and microsphere for controlled-release of exendin and method of preparing the same
CA2690858A1 (en) * 2007-06-07 2008-12-18 Surmodics Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
ATE514417T1 (en) 2007-12-21 2011-07-15 Merck Patent Gmbh SOLID LIPID MICROCAPSULATIONS WITH A GROWTH HORMONE INSIDE THE SOLID CORE
JP6078217B2 (en) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Powdered protein composition and method for producing the same
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2411137B1 (en) * 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
CN101559041B (en) 2009-05-19 2014-01-15 中国科学院过程工程研究所 Polypeptide medicament sustained release microsphere or microcapsule preparation with uniform grain size and preparation method thereof
MX342623B (en) 2009-06-26 2016-10-06 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
WO2011041642A1 (en) * 2009-10-01 2011-04-07 Surmodics Pharmaceuticals, Inc. Microparticle compositions and methods for treating age-related macular degeneration
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
JOP20190250A1 (en) 2010-07-14 2017-06-16 Regeneron Pharma Stabilized formulations containing anti-ngf antibodies
PT2600812T (en) 2010-08-05 2021-11-09 Forsight Vision4 Inc Implantable therapeutic device
CN105435338B (en) 2010-08-05 2019-03-26 弗赛特影像4股份有限公司 Injector apparatus and method for drug conveying
PL2624865T3 (en) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
SG10201602829PA (en) 2011-04-14 2016-05-30 Univ California Multilayer Thin Film Drug Delivery Device And Methods Of Making And Using The Same
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
CA2855749C (en) 2011-11-18 2020-05-26 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
EP2856259B1 (en) 2012-05-30 2018-12-26 The Regents of The University of California Bioactive agent delivery devices and methods of making and using the same
US9463177B2 (en) 2012-09-10 2016-10-11 The Regents Of The University Of California Compounds and methods for modulating vascular injury
CA2903345A1 (en) 2013-03-19 2014-09-25 Biotech Tools S.A. Allergen preparation
EP3169709B1 (en) 2014-07-14 2021-05-12 Amgen Inc. Crystalline antibody formulations
IL258570B2 (en) 2015-10-16 2024-07-01 Regeneron Pharma Stable protein compositions
EA201891071A1 (en) 2015-11-05 2018-11-30 Басф Се SUBSTITUTED OXADIAZOLES FOR FIGHT AGAINST PHYTOPATHOGEN MUSHROOMS
CN108473499B (en) 2015-11-13 2021-07-23 诺华股份有限公司 Novel pyrazolopyrimidine derivatives
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variants
EP3387062A2 (en) 2015-12-07 2018-10-17 Acetate International LLC Cellulose acetate film forming compositions
JP7184646B2 (en) 2015-12-15 2022-12-06 メルク・シャープ・アンド・ドーム・エルエルシー Biaryl monobactam compounds and methods of their use for treating bacterial infections
WO2017106716A1 (en) 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles

Also Published As

Publication number Publication date
MX2019000382A (en) 2023-01-05
US20130129830A1 (en) 2013-05-23
EP2790681B2 (en) 2023-02-22
IL262651A (en) 2018-12-31
IL262651B (en) 2020-11-30
PL3574897T3 (en) 2022-05-09
PL3384903T3 (en) 2020-10-19
PT3384903T (en) 2020-06-25
KR102218223B1 (en) 2021-02-22
SG11201402152YA (en) 2014-06-27
US11291636B2 (en) 2022-04-05
ZA201800078B (en) 2020-05-27
CA2855749C (en) 2020-05-26
CN105688188A (en) 2016-06-22
RU2018101248A (en) 2019-02-21
EP3574897A1 (en) 2019-12-04
EP2790681B1 (en) 2020-01-22
CA3076725A1 (en) 2013-05-23
DK2790681T4 (en) 2023-05-01
RU2018101248A3 (en) 2021-02-18
EP2790681B9 (en) 2023-07-26
EP3384903A1 (en) 2018-10-10
ES2775104T3 (en) 2020-07-23
PL2790681T5 (en) 2024-02-05
BR112014011915B1 (en) 2022-08-30
HUE048597T2 (en) 2020-07-28
ZA202000742B (en) 2024-06-26
RU2642664C2 (en) 2018-01-25
MX2014005997A (en) 2014-08-27
IL277958B2 (en) 2023-11-01
IL303832A (en) 2023-08-01
AU2012340107B2 (en) 2017-06-15
JP2020169195A (en) 2020-10-15
EP4026543B1 (en) 2024-08-07
CN103957898B (en) 2016-02-24
CN103957898A (en) 2014-07-30
JP2023052564A (en) 2023-04-11
EP4026543A1 (en) 2022-07-13
ES2775104T5 (en) 2023-06-08
ES2810003T3 (en) 2021-03-08
JP7542090B2 (en) 2024-08-29
IL277958A (en) 2020-11-30
JP2014533698A (en) 2014-12-15
KR20220063293A (en) 2022-05-17
DK3384903T3 (en) 2020-07-20
KR20210021112A (en) 2021-02-24
RU2014124682A (en) 2015-12-27
JP6549653B2 (en) 2019-07-24
FI2790681T4 (en) 2023-05-04
KR20200018712A (en) 2020-02-19
RU2768492C2 (en) 2022-03-24
AU2012340107A1 (en) 2014-06-05
DK3574897T3 (en) 2022-04-04
IL277958B1 (en) 2023-07-01
EP3574897B1 (en) 2022-01-05
US20240207194A1 (en) 2024-06-27
MX362286B (en) 2019-01-10
EP2790681A1 (en) 2014-10-22
US20220249387A1 (en) 2022-08-11
ES2909777T3 (en) 2022-05-10
KR102133352B1 (en) 2020-07-14
PL2790681T3 (en) 2020-07-27
US11951216B2 (en) 2024-04-09
CA2855749A1 (en) 2013-05-23
WO2013075068A1 (en) 2013-05-23
HUE051644T2 (en) 2021-03-01
EP3384903B1 (en) 2020-05-27
PT3574897T (en) 2022-04-06
IL232328B (en) 2018-11-29
JP2018008990A (en) 2018-01-18
ZA201403379B (en) 2020-12-23
KR20140096327A (en) 2014-08-05
JP7217247B2 (en) 2023-02-02
US20170181978A1 (en) 2017-06-29
IL232328A0 (en) 2014-06-30
JP6267649B2 (en) 2018-01-24
DK2790681T3 (en) 2020-04-14
BR112014011915A2 (en) 2017-05-16
JP2019135255A (en) 2019-08-15
JP6727372B2 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
IL277958A (en) Polymer protein microparticles
HK1198356A1 (en) Macromolecules
ZA201309001B (en) Polymer particles
EP2754747A4 (en) Molded inorganic-fiber object
GB2501047B (en) Polymer
GB201221246D0 (en) Polymer blends
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
GB2499491B (en) Compatibilised polymer blends
EP2733361A4 (en) Turbocompressor
GB201105482D0 (en) Polymers
PL2794110T3 (en) Granulator
EP2707420A4 (en) Polymers and plastics derived from animal proteins
GB201107468D0 (en) Protein expression systems
EP2728198A4 (en) Turbocompressor
EP2773330A4 (en) Processes for producing protein microparticles
GB201213672D0 (en) Protein
EP2714717A4 (en) Phoenixin peptides
EP2733360A4 (en) Turbocompressor
GB2487794B (en) Microparticles
AU2012905215A0 (en) Microparticles
GB201215901D0 (en) Protein modification
GB201103169D0 (en) Protein expression
HUP1100282A2 (en) Protein factor
GB201113089D0 (en) Protein hydrolysates